- Sartorius increased its full-year sales forecast, now expecting growth of around 7% compared to the previously estimated 6%.
- The company anticipates the adjusted EBITDA margin to exceed 29.5%, up from the earlier prediction of between 29% and 30%.
- In the first nine months, Sartorius reported sales of €2.61 billion, representing a year-over-year increase of 5.5%.
- The adjusted EBITDA for the first nine months is €774.2 million, marking a 13% year-over-year growth.
- Sartorius achieved an adjusted net income of €243.6 million, which is 17% higher compared to the previous year.
- The adjusted EBITDA margin stands at 29.7%, improved from 27.7% in the prior year.
- In the third quarter, Sartorius achieved sales of €843.2 million, slightly above the estimate of €833.8 million.
- The company’s guidance adjustment reflects the year-to-date performance, the anticipated impact of current tariffs, contributions from the MATTEK acquisition, and the strong comparison basis in Q4 2024.
- Analyst recommendations for Sartorius include 5 buy ratings, 2 hold ratings, and 1 sell rating.
Sartorius AG on Smartkarma
Analysts on Smartkarma are optimistic about Sartorius AG‘s future, as highlighted in recent research reports. Baptista Research‘s analysis, “Sartorius AG – Can U.S. Expansion Shield It from Global Trade Chaos?”, focuses on the company’s robust first-quarter results for 2025. Sartorius AG reported a 6.5% growth in sales revenue in constant currencies, reaching EUR 883 million, with a significant 12.2% increase in underlying EBITDA. The strong performance was primarily driven by the Bioprocess Solutions division, which saw a 10% rise in sales revenue, led by consumables.
Tina Banerjee‘s report, “Sartorius AG (SRT GR): Strong 1Q25 Result; Positive Takeaway For Bioprocessing Industry,” also echoes a positive sentiment. Sartorius witnessed a 21% year-on-year increase in net profit for the first quarter of 2025 on a 7% sales growth. The company anticipates a 6% sales growth for the year with an improved EBITDA margin. The outlook is particularly beneficial for the biopharma Contract Development and Manufacturing Organization (CDMO) sector. With the strong performance in the first quarter, analysts are optimistic about Sartorius AG‘s near-term growth prospects and its position in the biopharma industry.
A look at Sartorius AG Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at Sartorius AG can take heart in the company’s solid overall outlook as indicated by the Smartkarma Smart Scores. While specific numbers were not disclosed, Sartorius AG‘s scores reveal a balanced performance across key factors. The company scores moderately in Value, Dividend, and Growth categories, showcasing steady potential. Additionally, Sartorius AG demonstrates higher scores in Resilience and Momentum, indicating a robust ability to weather challenges and maintain positive market momentum.
Sartorius AG, a manufacturer of precision electronic equipment and components, has gained recognition for its global presence in providing precision scales for laboratory and industrial applications, along with a range of equipment for biomolecular and microbial processes. With a diversified product portfolio catering to various scientific fields, Sartorius AG‘s Smartkarma Smart Scores underline its promising long-term outlook, offering investors a glimpse into its balanced performance and potential for sustained growth in the evolving market landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
